marked.bio

Company

InventisBio

3 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

garsorasib 2ifebemtinib 1pembrolizumab 1cetuximab 1

Trials

3 of 6 trials shown

  1. Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors

    Active, not recruiting Phase 1/2 InventisBio Started 2022Primary completion 2027-12 NCT05379946

    garsorasibifebemtinib

    Subject has KRasG12C mutation in tumor tissue or other biospecimens (only for phase1b) containing cancer cells…

    KRAS G12CSolid Tumor

  2. Study to Evaluate D-1553 in Subjects With Solid Tumors

    Active, not recruiting Phase 1/2 InventisBio Started 2020Primary completion 2024-04 NCT04585035

    garsorasibpembrolizumabcetuximab

    Subject has KRasG12C mutation in tumor tissue or other bio-specimens containing cancer cells or DNA.

    KRAS G12CSolid Tumor, Adult, NSCLC, CRC

  3. A Study to Evaluate YF087 in Subjects With MSI-H or dMMR Advanced Solid Tumors

    Not yet recruiting Phase 1 InventisBio Started 2026Primary completion 2028-09 NCT07809607

    YF087

    A Study to Evaluate YF087 in Subjects With MSI-H or dMMR Advanced Solid Tumors

    MSI-H / dMMRAdvanced Solid Tumor Cancer